AUSTIN, Texas, March 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
AUSTIN, Texas, Oct. 23, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
New publication indicates that NPRL2 gene therapy has marked single-agent activity in anti-PD1 resistant non-small cell lung cancer xenografts The studies used the Company's non-viral ONCOPREX ...
AUSTIN, Texas, March 26, 2025 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
Both REQORSA Alone and in Combination with LUMAKRAS ® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas, April 30, 2025 /PRNewswire/ -- Genprex ...
The MarketWatch News Department was not involved in the creation of this content. Reqorsa(R) Gene Therapy is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer AUSTIN, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback